A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura

P. Jilma-Stohlawetz, J. C. Gilbert, M. E. Gorczyca, P. Knöbl, B. Jilma
  • Thrombosis and Haemostasis, August 2011, Schattauer GmbH
  • DOI: 10.1160/th11-02-0069
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Professor Paul Knoebl